NASDAQ:INZY
Inozyme Pharma, Inc. Stock News
$4.60
-0.130 (-2.75%)
At Close: May 17, 2024
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 03'rd Nov 2023
BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY)(“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for
Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
01:33pm, Tuesday, 10'th Oct 2023
Inozyme Pharma, Inc. (INZY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeut
BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeut
Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023
08:30am, Wednesday, 20'th Sep 2023
Company to share interim data updates from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) Company to share interim data updates from ongoing Phase 1/2 t
Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08:30am, Tuesday, 05'th Sep 2023
BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mi
3 Penny Stocks To Buy According To Insiders In August 2023
10:54am, Friday, 04'th Aug 2023
Penny stocks are an interesting asset class when it comes to making money in the stock market. Their inherent risk/reward makeup lends to heavy speculation and a thirst for significant gains.
Inozyme Pharma to Present at the Jefferies Healthcare Conference
07:30am, Friday, 02'nd Jun 2023
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic min
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic m
Pivotal bioVenture Partners Fund I Now Owns 7.4% of Inozyme Pharma
10:25pm, Wednesday, 05'th Apr 2023
Fintel reports that Pivotal bioVenture Partners Fund I has filed a 13D/A form with the SEC disclosing ownership of 3.21MM shares of Inozyme Pharma Inc (INZY).
Inozyme Pharma: Rare Disease Player Merits Revaluation Higher After POC Data
04:51pm, Tuesday, 21'st Feb 2023
Shares are down 58% over the past year. Enzyme replacement therapy is an attractive area of drug development with less risk than more exotic modalities like gene therapy.
Choosing Penny Stocks for Short Term Trading; 3 Tips
06:00am, Tuesday, 21'st Feb 2023
Use these tips for trading penny stocks in the short term The post Choosing Penny Stocks for Short Term Trading; 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks
Inozyme Pharma to Participate in Upcoming Investor Conferences
07:30am, Monday, 07'th Nov 2022
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic min
Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference
07:30am, Tuesday, 06'th Sep 2022
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, t
Inozyme Pharma Post Encouraging Early Data From Genetic Disorder Trial
11:04am, Wednesday, 20'th Jul 2022
Inozyme Pharma Inc (NASDAQ: INZY) has announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three subjects in the Phase 1 portion of its ongoing Phase 1/2 trial of I